MedPath

Effect of sumac on Clinical, Hormonal and inflammatory signs and blood sugar and lipids amount in women with polycystic ovary syndrome

Not Applicable
Conditions
Polycystic ovary syndrome.
Poly cystic ovarian syndrome
Registration Number
IRCT20120415009472N17
Lead Sponsor
Iran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Female
Target Recruitment
88
Inclusion Criteria

Patients with polycystic ovary syndrome based on two criteria of the three diagnostic criteria of the disease based on Rotterdam1. Reduction of bleeding or discontinuation (as: Delay more than 35 days or less than 8 bleeding episodes per year); 2. Clinical symptoms including hirsutism or Ferriman-Gallwey (MFG) score above 8,acne and Male pattern baldness, biochemical symptoms of increased endogenesis ,3.polycystic ovary (12 or more of 12 follicles per ovary with diameter of 2 to 9 mm , or an increase in ovarian volume to more than 310 ml)
Reduction of bleeding or discontinuation (as: Delay more than 35 days or less than 8 bleeding episodes per year);
Clinical symptoms including hirsutism or Ferriman-Gallwey (MFG) score above 8,acne and Male pattern baldness
biochemical symptoms of increased endogenesis
polycystic ovary (12 or more of 12 follicles per ovary with diameter of 2 to 9 mm , or an increase in ovarian volume to more than 310 ml)
Age 20 to 40 years old
Having informed written consent

Exclusion Criteria

Taking drug of anticoagulants and hyperlipidemia
Use of Tobacco
Having kidney disease, diabetes, liver disease, cardiovascular disorders, hypothyroidism, inflammatory and rheumatic diseases, hyperprolactinemia, Cushing's syndrome and congenital adrenal hyperplasia
Follow a particular diet in the last three months
Taking medications that affect insulin sensitivity, inflammation, or lipid profile and hormonal profile, including glucocorticoid drugs, ovulation induction drugs, anti-obesity, anti-diabetes, antihypertensive, estrogenic, anti-androgen, over the past 3 months
Unwilling to participate in the study
Use of Nutrition Supplements in the last 2 months
Pregnancy or breastfeeding
Sensitization or allergy to sumac

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath